Acromegaly is a rare condition typically caused by benign pituitary adenomas, resulting in excessive production of growth hormone. Clinical manifestations of acromegaly are diverse, varying from the overgrowth of body tissue to cardiovascular, metabolic, and osteoarticular disorders. Symptoms may emerge slowly, overlapping with other diseases and often involve many different healthcare specialists. In the last decade, efforts to provide an accurate and timely diagnosis of acromegaly have improved disease management and clinical experience. Despite this progress, marked differences in the diagnosis, treatment, and management of acromegaly exist from country-to-country. To address these inconsistencies in the region comprising Central and Eastern Europe, Israel, and Kazakhstan, a panel of acromegaly experts from 13 of these countries was convened. Acromegaly experts from each country provided available information on the approaches from their country, including regional treatment centers and multidisciplinary teams, treatment access, reimbursement and availability, and physician education, disease awareness, and patient advocacy. Across several areas of acromegaly management, divergent approaches were identified and discussed, including the provision of multidisciplinary care, approved and available treatments, and disease awareness programs. These were recognized as areas of potential improvement in the management of acromegaly, in addition to participation in national and regional acromegaly registries. Further experience exchange will facilitate the identification of specific strategies that can be adapted in each country, and widespread participation in acromegaly registries will enable their evaluation. It is anticipated that this approach will support the optimization of acromegaly patient care across this region.

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Central and Eastern Europe Medical Affairs Pfizer Rare Disease Paris France

Comenius University Faculty of Medicine 5th Department of Internal Medicine University Hospital Bratislava Bratislava Slovakia

Department of Endocrinology Carol Davila University of Medicine and Pharmacy Bucharest Romania

Department of Endocrinology Diabetes and Isotope Therapy Wroclaw Medical University Wroclaw Poland

Department of Endocrinology Diabetes and Metabolic Diseases University Medical Centre Ljubljana Ljubljana Slovenia

Department of Endocrinology Specialized Hospital for Active Treatment of Endocrinology Medical University Sofia Bulgaria

Department of Endocrinology University Hospital Center Zagreb Zagreb Croatia

Department of Internal Medicine and Oncology Semmelweis University Budapest Hungary

Department of Transsphenoidal Surgery Romodanov Neurosurgery Institute Kyiv Ukraine

Division of Endocrinology and Metabolism Bar Ilan Faculty of Medicine Clalit Medical Health Care Services Safed Israel

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Global Medical Affairs Pfizer Rare Disease Brussels Belgium

Kazakh National Medical University Almaty Kazakhstan

Medical Affairs Pfizer Rare Disease Bucharest Romania

Neuroendocrine Unit Endocrinology Department Moscow Regional Research and Clinical Institute Moscow Russia

Neuroendocrinology Department Clinic for Endocrinology Diabetes and Metabolic Diseases Clinical Centre of Serbia Medical Faculty University of Belgrade Belgrade Serbia

Rabin Medical Center Petah Tikva and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Zobrazit více v PubMed

Maione L, Chanson P. National Acromegaly Registries. Best Pract Res Clin Endocrinol Metab (2019) 33:101264. doi: 10.1016/j.beem.2019.02.001 PubMed DOI

Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, et al. . Signs and Symptoms of Acromegaly at Diagnosis: The Physician's and the Patient's Perspectives in the ACRO-POLIS Study. Endocrine (2019) 63:120–9. doi: 10.1007/s12020-018-1764-4 PubMed DOI PMC

Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. . Acromegaly. Nat Rev Dis Primers (2019) 5:20. doi: 10.1038/s41572-019-0071-6 PubMed DOI

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, et al. . Acromegaly at Diagnosis in 3173 Patients From the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer (2017) 24:505–18. doi: 10.1530/ERC-17-0253 PubMed DOI PMC

Dreval AV, Pokramovich YG, Nechaeva O, Shestakova T, Trigolosova IV, Ilovayskaya IA. Symptoms and Sign of Active Acromegaly in Patients From Moscow Region. In: Endocrine Society’s 96th Annual Meeting and Expo. Chicago: Endocrine Reviews; (2014). p. i1–i1153. June 21–24, 2014.

Khyzhnyak OM, Mykytyuk M, Guk M, Nikolaiev R, Gogitidze T. Clinical and Hormonal Features of Acromegaly in Patients From a Ukrainian Neuroendocrinology Centre. Prob Endocr Pathol (2019) 68:119–30. doi: 10.21856/j-PEP.2019.2.17 DOI

Nikolaiev RR, Rostomyan L, Beckers A, Tsymbaliuk V, Khyzhnyak O, Guk M, et al. . Acromegaly Combined With Gigantism Associated With the AIP-Gene Mutation: A Clinical Case. Problems Endocrine Pathol (2021) 75:43–51. doi: 10.21856/j-PEP.2021.1.06. DOI

Prencipe N, Floriani I, Guaraldi F, Di Giacomo SV, Cannavo S, Arnaldi G, et al. . ACROSCORE: A New and Simple Tool for the Diagnosis of Acromegaly, a Rare and Underdiagnosed Disease. Clin Endocrinol (Oxf) (2016) 84:380–5. doi: 10.1111/cen.12959 PubMed DOI

Antsiferov MB, Pronin VS, Alekseeva TM, Ionova OA, Martynova EY, Poteshkin YE, et al. . Selective Screening of Patients With Associated Somatic Diseases as a Method of Early Detection of Acromegaly. Probl Endokrinol (Mosk) (2021) 67:20–30. doi: 10.14341/probl12699 PubMed DOI PMC

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. . A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab (2020) 105:e937–46. doi: 10.1210/clinem/dgz096 PubMed DOI

Colao A, Vandeva S, Pivonello R, Grasso LFS, Nachev E, Auriemma RS, et al. . Could Different Treatment Approaches in Acromegaly Influence Life Expectancy? A Comparative Study Between Bulgaria and Campania (Italy). Eur J Endocrinol (2014) 171:263–73. doi: 10.1530/EJE-13-1022 PubMed DOI

Rolla M, Jawiarczyk-Przybylowska A, Halupczok-Zyla J, Kaluzny M, Konopka BM, Bloniecka I, et al. . Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center. Front Endocrinol (Lausanne) (2021) 12:642131. doi: 10.3389/fendo.2021.642131 PubMed DOI PMC

Bolanowski M, Zgliczynski W, Sowinski J, Baldys-Waligorska A, Bednarek-Tupikowska G, Witek P, et al. . Therapeutic Effect of Presurgical Treatment With Longacting Octreotide (Sandostatin® LAR®) in Patients With Acromegaly. Endokrynol Pol (2020) 71:285–91. doi: 10.5603/EP.a2020.0050 PubMed DOI

Shestakova T, Dreval A, Nechaeva O, Zakharevich E, Ilovayskaya IA. Gender Differences in Thyroid Abnormalities at Patients With Acromegaly: SAT-748. In: The Endocrine Society’s 94th Annual Meeting and Expo. Houston, TX: Endocrine Reviews; (2012). p. i1–i1057. June 23–26, 2012.

Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, et al. . Prevalence of Diabetes Mellitus in Patients With Acromegaly. Endocr Connect (2014) 3:93–8. doi: 10.1530/EC-14-0021 PubMed DOI PMC

Baldys-Waligorska A, Krzentowska A, Golkowski F, Sokolowski G, Hubalewska-Dydejczyk A. The Prevalence of Benign and Malignant Neoplasms in Acromegalic Patients. Endokrynol Pol (2010) 61:29–34. PubMed

Tsoy UA, Korostovtseva LS, Sviryaev YV, Semenov AP, Vaulina DA, Kravchenko SO, et al. . Prevalence of Sleep Disordered Breathing in Patients With Newly Diagnosed Acromegaly. Almanac Clin Med (2014) 32:36–42. doi: 10.18786/2072-0505-2014-32-36-42 DOI

Titaeva AA, Tereshchenko SG, Lukina EM, Dreval AV, Ilovaiskaya IA. Background Changes of the Digestive System Mucosa in Patients With Acromegaly. Almanac Clin Med (2014) 31:29–33. doi: 10.18786/2072-0505-2014-31-29-33 DOI

Kovaleva YA, Dreval AV, Kulakov NV, Fedorova SI, Ilovayskaya IA. Prevalence and Risk Factors of Sleep Breathing Disorders in Patients With Acromegaly From Moscow Region. Ter Arkh (2018) 90:65–70. doi: 10.26442/terarkh2018901065-70 PubMed DOI

Dreval A, Logutova L, Zaydieva Y, Stashuk G, Perfilyev A, Ilovayskaya IA. Menstrual Function in Women of Reproductive Age With Acromegaly. Endocrine Abstracts (2013) 32:612. doi: 10.1530/endoabs.32.P612 DOI

Kamusheva M, Vandeva S, Mitov K, Rusenova Y, Elenkova A, Zacharieva S, et al. . New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. Front Public Health (2020) 8:147. doi: 10.3389/fpubh.2020.0014 PubMed DOI PMC

Stelmachowska-Banas M, Zdunowski P, Zgliczynski W. Abnormalities in Glucose Homeostasis in Acromegaly. Does the Prevalence of Glucose Intolerance Depend on the Level of Activity of the Disease and the Duration of the Symptoms? Endokrynol Pol (2009) 60:20–4. PubMed

Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T, Perkovic Z, et al. . Clinical Features and Therapeutic Outcomes of Patients With Acromegaly: Single-Center Experience. J Endocrinol Invest (2011) 34:e382–5. doi: 10.3275/7858 PubMed DOI

Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. . Changes in the Management and Comorbidities of Acromegaly Over Three Decades: The French Acromegaly Registry. Eur J Endocrinol (2017) 176:645–55. doi: 10.1530/EJE-16-1064 PubMed DOI

Kuzma M, Vanuga P, Sagova I, Pavai D, Jackuliak P, Killinger Z, et al. . Non-Invasive DXA-Derived Bone Structure Assessment of Acromegaly Patients: A Cross-Sectional Study. Eur J Endocrinol (2019) 180:201–11. doi: 10.1530/EJE-18-0881 PubMed DOI

Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, et al. . Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study. J Clin Endocrinol Metab (2013) 98:3402–10. doi: 10.1210/jc.2013-1460 PubMed DOI

Kuzma M, Vanuga P, Sagova I, Pavai D, Jackuliak P, Killinger Z, et al. . Vertebral Fractures Occur Despite Control of Acromegaly and are Predicted by Cortical Volumetric Bone Mineral Density. J Clin Endocrinol Metab (2021) 106:e5088–96. doi: 10.1210/clinem/dgab259 PubMed DOI

Kastelan D, Dusek T, Kraljevic I, Polasek O, Perkovic Z, Kardum I, et al. . Bone Properties in Patients With Acromegaly: Quantitative Ultrasound of the Heel. J Clin Densitom (2007) 10:327–31. doi: 10.1016/j.jocd.2007.03.103 PubMed DOI

Ciresi A, Guarnotta V, Campo D, Giordano C. Hepatic Steatosis Index in Acromegaly: Correlation With Insulin Resistance Regardless of the Disease Control. Int J Endocrinol (2018) 2018:5421961. doi: 10.1155/2018/5421961 PubMed DOI PMC

Koutsou-Tassopoulou A, Papapostoli-Sklavounou I, Krawczyk M, Friesenhahn-Ochs B, Weber SN, Lammert F, et al. . Hepatic Steatosis in Patients With Acromegaly. Endocrinol Diabetes Metab (2019) 2:e00090. doi: 10.1002/edm2.90 PubMed DOI PMC

Jawiarczyk-Przybylowska A, Halupczok-Zyla J, Kolackov K, Gojny L, Zembska A, Bolanowski M. Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients. Front Endocrinol (Lausanne) (2019) 10:643. doi: 10.3389/fendo.2019.00643 PubMed DOI PMC

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. . A Consensus Statement on Acromegaly Therapeutic Outcomes. Nat Rev Endocrinol (2018) 14:552–61. doi: 10.1038/s41574-018-0058-5 PubMed DOI PMC

Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. . Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2014) 99:3933–51. doi: 10.1210/jc.2014-2700 PubMed DOI

Bolanowski M, Ruchala M, Zgliczynski W, Kos-Kudla B, Hubalewska-Dydejczyk A, Lewinski A. Diagnostics and Treatment of Acromegaly - Updated Recommendations of the Polish Society of Endocrinology. Endokrynol Pol (2019) 70:2–18. doi: 10.5603/EP.a2018.0093 PubMed DOI

Molitvoslovova NN, Rozhinskaya LY, Melnichenko GA. [Russian Consensus on the Diagnosis, Treatment, and Monitoring of Acromegalia (Draft)]. Probl Endokrinol (Mosk) (2007) 53:37–41. doi: 10.14341/probl200753437-41 PubMed DOI

Marinescu MC, Baciu I, Baculescu N, Capatina CAM, Dusceac R, Galoiu S, et al. . Improvement of Acromegaly Control With Multimodal Therapy in Romania. Endokrynol Pol (2020) 71:235–9. doi: 10.5603/EP.a2020.0020 PubMed DOI

Doknić M, Stojanović M. The Place of Medical Treatment of Acromegaly in Serbia: Current Status. Vojnosanitetski Pregled (2021) 78:1088–95. doi: 10.2298/VSP200120036D DOI

Elbaum M, Mizera L, Bolanowski M. The Real Costs of Acromegaly: Analysis of Different Therapies. Endokrynol Pol (2019) 70:74–85. doi: 10.5603/EP.a2018.0080 PubMed DOI

Leonart LP, Borba HHL, Ferreira VL, Riveros BS, Pontarolo R. Cost-Effectiveness of Acromegaly Treatments: A Systematic Review. Pituitary (2018) 21:642–52. doi: 10.1007/s11102-018-0908-0 PubMed DOI

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. . A Pituitary Society Update to Acromegaly Management Guidelines. Pituitary (2021) 24:1–13. doi: 10.1007/s11102-020-01091-7 PubMed DOI PMC

Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, et al. . High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. J Clin Endocrinol Metab (2017) 102:2454–64. doi: 10.1210/jc.2017-00142 PubMed DOI

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. . Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. J Clin Endocrinol Metab (2014) 99:791–9. doi: 10.1210/jc.2013-2480 PubMed DOI PMC

Gadelha M, Bex M, Colao A, Pedroza Garcia EM, Poiana C, Jimenez-Sanchez M, et al. . Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Front Endocrinol (Lausanne) (2019) 10:931. doi: 10.3389/fendo.2019.00931 PubMed DOI PMC

Coopmans EC, Muhammad A, van der Lely AJ, Janssen J, Neggers S. How to Position Pasireotide LAR Treatment in Acromegaly. J Clin Endocrinol Metab (2019) 104:1978–88. doi: 10.1210/jc.2018-01979 PubMed DOI

Shimon I, Adnan Z, Gorshtein A, Baraf L, Saba Khazen N, Gershinsky M, et al. . Efficacy and Safety of Long-Acting Pasireotide in Patients With Somatostatin-Resistant Acromegaly: A Multicenter Study. Endocrine (2018) 62:448–55. doi: 10.1007/s12020-018-1690-5 PubMed DOI

Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, et al. . Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. J Clin Endocrinol Metab (2019) 104:2892–902. doi: 10.1210/jc.2018-02281 PubMed DOI

Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, et al. . Long-Term Treatment With Pegvisomant: Observations From 2090 Acromegaly Patients in ACROSTUDY. Eur J Endocrinol (2018) 179:419–27. doi: 10.1530/EJE-18-0616 PubMed DOI

Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R. Effectiveness and Safety of Pegvisomant: A Systematic Review and Meta-Analysis of Observational Longitudinal Studies. Endocrine (2019) 63:18–26. doi: 10.1007/s12020-018-1729-7 PubMed DOI

Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, et al. . Pegvisomant in Acromegaly: An Update. J Endocrinol Invest (2017) 40:577–89. doi: 10.1007/s40618-017-0614-1 PubMed DOI PMC

Qiao N, He M, Shen M, Zhang Q, Zhang Z, Shou X, et al. . Comparative Efficacy of Medical Treatment for Acromegaly: A Systematic Review and Network Meta-Analysis of Integrated Randomized Trials and Observational Studies. Endocr Pract (2020) 26:454–62. doi: 10.4158/EP-2019-0528 PubMed DOI

Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK. Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly With the GH Receptor Antagonist Pegvisomant. Eur J Endocrinol (2018) 178:321–9. doi: 10.1530/EJE-17-0996 PubMed DOI PMC

Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schöfl C, Schopohl J, et al. . Fractionated Radiotherapy and Radiosurgery in Acromegaly: Analysis of 352 Patients From the German Acromegaly Registry. Eur J Endocrinol (2020) 182:275–84. doi: 10.1530/EJE-19-0784 PubMed DOI

Ding D, Mehta GU, Patibandla MR, Lee CC, Liscak R, Kano H, et al. . Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study. Neurosurgery (2019) 84:717–25. doi: 10.1093/neuros/nyy178 PubMed DOI PMC

Ježkova J, Marek J, Hána V, Kršek M, Weiss V, Vladyka V, et al. . Gamma Knife Radiosurgery for Acromegaly–Long-Term Experience. Clin Endocrinol (Oxf) (2006) 64:588–95. doi: 10.1111/j.1365-2265.2006.02513.x PubMed DOI

Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical Investigations in Diagnosis and Follow Up of Acromegaly. Pituitary (2017) 20:33–45. doi: 10.1007/s11102-017-0792-z PubMed DOI

Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, et al. . Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. J Clin Endocrinol Metab (2017) 102:2844–52. doi: 10.1210/jc.2017-00202 PubMed DOI

Belaya ZE, Golounina OO, Rozhinskaya LY, Melnichenko GA, Isakov MA, Lutsenko AS, et al. . [Epidemiology, Clinical Manifestations and Efficiency of Different Methods of Treatment of Acromegaly According to the United Russian Registry of Patients With Pituitary Tumors]. Probl Endokrinol (Mosk) (2020) 66:93–103. doi: 10.14341/probl10333 PubMed DOI

Niculescu DA, Baciu IF, Capatina C, Galoiu SA, Gheorghiu ML, Radian S, et al. . Acromegaly Treatment in Romania. How Close are We to Disease Control? Endokrynol Pol (2017) 68:519–23. doi: 10.5603/EP.a2017.0041 PubMed DOI

Masri-Iraqi H, Akirov A, Shimon I. Medical Treatment Landscape for Active Acromegaly in a Pituitary Center in Israel. Endocr Pract (2020) 26: 1298–303. doi: 10.4158/EP-2020-0171 PubMed DOI

van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, et al. . Development of ACRODAT(®), a New Software Medical Device to Assess Disease Activity in Patients With Acromegaly. Pituitary (2017) 20:692–701. doi: 10.1007/s11102-017-0835-5 PubMed DOI PMC

Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, et al. . SAGIT®: Clinician-Reported Outcome Instrument for Managing Acromegaly in Clinical Practice–Development and Results From A Pilot Study. Pituitary (2016) 19:39–49. doi: 10.1007/s11102-015-0681-2 PubMed DOI PMC

Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, et al. . Staging and Managing Patients With Acromegaly in Clinical Practice: Baseline Data From the SAGIT® Validation Study. Pituitary (2019) 22:476–87. doi: 10.1007/s11102-019-00977-5 PubMed DOI PMC

Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH, et al. . Development of a Novel Patient-Reported Measure for Acromegaly: The Acro-TSQ. Pituitary (2019) 22:581–93. doi: 10.1007/s11102-019-00986-4 PubMed DOI PMC